Changes in lung cancer tumor markers should be paid attention to in the process of cancer diagnosis and treatment, significantly when Cyfra 21-1, NSE, and CEA are elevated simultaneously; timely attention should be paid to whether there is the occurrence of bone metastasis. This evidence concerns the gene ENO2 and lung carcinoma.